Overview

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as

Status:
Completed

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

Summary

This is a single dose study in healthy male volunteers to investigate the effect of high doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca
Pfizer

Treatments:

Avibactam
Ceftaroline fosamil
Ceftazidime
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination